Natco Pharma Limited

Type: Company
Name: Natco Pharma Limited (NATCO Pharma Limited)
First reported Sep 18 2014 - Updated Sep 19 2014 - 3 reports

Natco's Formulation Facility at Kothur found acceptable by USFDA

Natco's Kothur Formulation Facility found acceptable by USFDA Natco has received a letter dated July 14th 2014 after completing review of the Establishment Inspection Report (EIR) for the inspection conducted from May 19th to 23rd, 2014.The Facility was ... [Published Equity Bulls - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 2 reports

Kothur formulation facility acceptable to USFDA, says Natco

Source: IRIS (18-SEP-14)Comments | Post CommentNatco Pharma, a mid-size pharmaceutical company, clarified Thursday the US Food and Drug Administration (USFDA) has classified the company's Kothur formulation facility as acceptable following inspection ... [Published MyIris - Sep 18 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Sensex surges over 300 pts: Top 10 stocks in focus

NEW DELHI: Indian markets are expected to trade in a range on Thursday, tracking muted trend seen in other Asian markets and SGX Nifty.After two days of sharp fall, the benchmarks took a pause on Wednesday and gained nearly half a percent in a range bound ... [Published Economic Times - Sep 18 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Nifty reclaims 8050, Sensex rallies over 200 points; top ten stocks in focus

NEW DELHI: The S&P BSE Sensex which plunged over 100 points in trade on Thursday managed to bounce back 377 points from intraday low of 26503.08, led by gains in TCS, ITC, ICICI Bank, RIL and L&T.Tracking the momentum, the 50-share Nifty index also posted ... [Published Economic Times - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Natco Pharma, Orchid Chemicals get a strong dose of US FDA medicine

Natco Pharma and Orchid Chemicals and Pharmaceuticals have received an adverse observation report, commonly known as Form 483, after inspections conducted in their manufacturing units earlier this year by the US Food and Drug Administration, according ... [Published Financial Express - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 17 2014 - 1 reports

Individual stocks outperform Sensex; over 400 stocks hit 52-week high on BSE

NEW DELHI: The S&P BSE Sensex plunged over 300 points in trade on Tuesday, but that didn't bother traders to cherry pick quality stocks at lower levels in the small and midcap space.Bucking the overall markets trend, the real action was seen in small ... [Published Economic Times - Sep 16 2014]
First reported Sep 05 2014 - Updated Sep 06 2014 - 3 reports

Sensex closes 59 points lower at 27,026.70 points [Mint, New Delhi :: ]

Sept. 05--MUMBAI -- The 30-share benchmark S&P BSE Sensex closed nearly 60 points lower on Friday, led by weakness in shares of banking and auto companies.Investors were also cautious ahead of the Supreme Court's verdict in the coal block allocations ... [Published BusinessWeek - Sep 05 2014]
First reported Sep 05 2014 - Updated Sep 06 2014 - 6 reports

Natco’s US partner files ANDA for Everolimus

HYDERABAD: Drug maker Natco Pharma Ltd on Friday said its marketing partner in the US Breckenridge Pharmaceutical Inc (BPI) has filed an Abbreviated New Drug Application (ANDA) for Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets."Natco and BPI believe that ... [Published Times of India - Sep 06 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 2 reports

Midcap-Monitor: Natco Pharma, Unitech among top gainers

Even though the benchmark indices are trading at record highs the broader markets have outperformed as investors are now seen bargain hunting in the mid-cap and small-cap segments.The broader markets hit record highs after better-than-expected GDP growth ... [Published Smart Investor - Sep 01 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 7 reports

Natco's US marketing partner files ANDA for 'Copaxone'

Natco Pharma's marketing partner in the USA, Mylan Inc., has filed an Abbreviated New Drug Application (ANDA) for a three-times-a-week generic COPAXONE (glatiramer acetate injection, 40 mg/mL) and has been accepted by the US Food and Drug Administration ... [Published Indian-Commodity - Sep 01 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 2 reports

Natco Pharma’s partner Mylan files for Copaxone generic

An Abbreviated New Drug Application (ANDA) for three-times-a-week generic Copaxone (glatiramer acetate injection) filed by Mylan Inc has been accepted by the US Food and Drug Administration (US FDA).According to a released issued by Natco Pharma Ltd here ... [Published Hindu Business Line - Aug 30 2014]
First reported Aug 26 2014 - Updated Aug 27 2014 - 2 reports

Natco Pharma Ltd appoints Additional Directors

Exim Bank has with drawn their Nominee Director from the Board of Directors of Natco Pharma Ltd and the Board of Directors by way Resolution by circulation appointed Mr. T V Rao as Additional Directors of the Company.Dr. Mrs. Leela Digumarti, appointed ... [Published Equity Bulls - Aug 27 2014]

Quotes

The company has made proposed commitments and corrective actions based on the minor and routine observations during inspection. "We continue to manufacture and sell products in the US. We strongly deny all adverse speculations against the company" the company said
"Broadly, we expect Nifty to decline further in coming sessions and consolidate around 7800 prior to any major directional move" he added
"What I am trying to put across the point is that individual stocks during the course of the rally in the market, may face some amount of resistance, but these stocks should be bought into the portfolio" he added
"So will I buy Natco at Rs 1500 ex Copaxone for a two-three years horizon, because the drug pipeline is very strong. I think five years down the line when you look back on this company, it would be one of those companies where you would look at as an emerging company or something of that sort" he said

More Content

All (106) | News (91) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Gilead Emerging Market Agreement: Huge Win For ... [Published Seeking Alpha - Sep 19 2014]
Natco's Formulation Facility at Kothur found ac... [Published Equity Bulls - Sep 19 2014]
Kothur formulation facility acceptable to USFDA... [Published MyIris - Sep 18 2014]
USFDA recognizes Natco Pharma's Kothur Formulat... [Published Indian-Commodity - Sep 18 2014]
Sensex surges over 300 pts: Top 10 stocks in focus [Published Economic Times - Sep 18 2014]
Nifty reclaims 8050, Sensex rallies over 200 po... [Published Economic Times - Sep 18 2014]
Natco's Kothur formulation facility found accep... [Published MyIris - Sep 18 2014]
Natco's Kothur formulation facility found accep... [Published Moneycontrol.com - Sep 18 2014]
Natco Pharma, Orchid Chemicals get a strong dos... [Published Financial Express - Sep 17 2014]
Individual stocks outperform Sensex; over 400 s... [Published Economic Times - Sep 16 2014]
Vaibhav Choukse: Sweetheart deals that hurt con... [Published Business Standard India - Sep 15 2014]
FIIs, MFs take different paths [Published Hindu Business Line - Sep 14 2014]
Buy Natco Pharma: Rahul Arora [Published Moneycontrol.com - Sep 12 2014]
Compulsory license revisited - India [Published Lexology - Sep 11 2014]
Policy on intellectual property rights likely i... [Published Livemint.com - Sep 08 2014]
Indices zoom to life-time high...Tyre stocks on... [Published India Infoline - Sep 08 2014]
Nifty hits 8,150 mark; ONGC, Bajaj Auto top gai... [Published Business Standard India - Sep 08 2014]
Stock market prediction for September 8-12: Sat... [Published Moneycontrol.com - Sep 08 2014]
Huge strategies by pharma companies [Published Business Standard India - Sep 07 2014]
Natco’s US partner files ANDA for Everolimus [Published Times of India - Sep 06 2014]
Breckenridge Pharmaceutical, Inc. Announces Par... [Published Indianapolis Business Journal - Sep 05 2014]
Sensex closes 59 points lower at 27,026.70 poin... [Published BusinessWeek - Sep 05 2014]
Natco pharma's US partner files ANDA for Everol... [Published Moneycontrol.com - Sep 05 2014]
Weekly: Caution sets in after Sensex crosses 27000 [Published India Infoline - Sep 05 2014]
Modest losses for Sensex, Nifty...broader indic... [Published India Infoline - Sep 05 2014]
Markets end lower; Sensex holds 27,000 [Published Business Standard India - Sep 05 2014]
Sensex trades 85 points lower; CIL, Bhel fall [... [Published BusinessWeek - Sep 05 2014]
Natco Pharma's marketing partner Breckenridge P... [Published Business Standard India - Sep 05 2014]
Corporate : Natco's US marketing partner files ... [Published Indian-Commodity - Sep 05 2014]
Sensex down over 100 points as financials drag [Published Business Standard India - Sep 05 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Court Report [Published Patent Docs - Jun 01 2014]
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cephalon Inc. v. Breckenridge Pharmaceutical Inc. et al. 1:14-cv-00671; filed May 27, 2014 in the District Court of Delaware•Plaintiff: ...
6 Drugs That Could Move the Market [Published Wall St. Cheat Sheet - Apr 29 2014]
Overview In the last few years, a number of promising drugs that treat serious conditions and diseases have come through drugmakers’ pipelines. Recent developments in oncology, for instance, mean that there are more promising, potential blockbuster ...
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed... [Published Patent Docs - Apr 29 2014]
By Kevin E. Noonan -- The Federal Circuit extended the scope of the judicially created doctrine of obviousness-type double patenting (OTDP) in a split decision rendered in Gilead Sciences Inc. v. Natco Pharma Ltd. In doing so, the panel majority applied ...
Federal Circuit Rules for Axinn Client Natco Ph... [Published EON Business - Apr 25 2014]
HARTFORD, Conn.--(EON: Enhanced Online News)--A ruling by the U.S. Court of Appeals for the Federal Circuit has given Axinn, Veltrop & Harkrider LLP client Natco Pharma Ltd. a second chance at invalidating Gilead Sciences Inc.’s patent on the popular ...
Federal Circuit Rules for Axinn Client Natco Ph... [Published Business Wire Professional Services News - Apr 25 2014]
HARTFORD, Conn.--(BUSINESS WIRE)--A ruling by the U.S. Court of Appeals for the Federal Circuit has given Axinn, Veltrop & Harkrider LLP client Natco Pharma Ltd. a second chance at invalidating Gilead Sciences Inc.’s patent on the popular flu drug Tamiflu. ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.